Brendan Walkden
Brendan WalkdenPrincipal, London
Education: PhD in Biochemistry

Brendan has been with Deallus for over 4 years and has extensive experience in providing strategic business insights to support key marketing and investment decisions. He has supported brands from early pre-launch through to patent expiration, and has worked across a wide range of therapy areas including HIV, anti-fungals, pain and diabetes. Brendan has experience with managing market analysis, forecasting, and primary market research projects supporting brands at all stages of the product lifecycle.

Prior to joining Deallus in the London office, Brendan worked for 12 years in the business insights groups for several major pharmaceutical and biotech companies, most recently completing an assignment in the global analytics group for AstraZeneca working on the in-line and early emerging assets in the anti-infective franchise. He has also supported major market launches for Lundbeck and Amgen, working in the fields of mental health and osteoporosis and helping to develop brand strategies for the UK market.